GoTrust’s Idem Key Is the First USB/NFC Security Key, Working Across All User Devices, to Be Granted a FIDO2 Security Level 2
23.3.2021 18:00:00 EET | Business Wire | Press release
Today, GoTrustID Inc. (GoTrust) announced that their Idem Keys have been upgraded from FIDO2 Security Level 1 to Security Level 2 certification for passwordless login for devices, applications and cloud services. The Idem Keys have USB-A, USB-C and NFC interfaces. All GoTrust Idem Keys work with Windows, MAC, Chromebook, iOS and Android phones. The Idem Key can also be used for physical access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005056/en/
GoTrust FIDO2 Security Level 2 Idem Key, mojeID Identity service provided by CZ.NIC (Photo: Business Wire)
An eager customer for the GoTrust Level 2 Idem Key is the mojeID Identity service provided by CZ.NIC. Authorized by the Czech Ministry of the Interior, mojeID is able to access online government services. There are 700,000 users registered with mojeID today.
Going forward, to access more sensitive sites that require the highest level of assurance (LoA) such as opening a bank account or potentially in the future transferring property in property registry, mojeID users will need to use a FIDO2 Security Level 2 token with a security element certified by FIPS/CC. The only such token on the market today that works across every user device is the GoTrust Idem Key. “We were delighted to find exactly the token we required to get LoA High accreditation,” commented Ondřej Filip, CEO at CZ.NIC. “Cooperation with GoTrustID Inc. has been perfect since the beginning and we really admire their decision to go the through L2 certification process.”
Shipment of Idem Keys to CZ.NIC has already started and is expected to grow rapidly as the demand for the highest LoA services increases.
About GoTrustID Inc.
GoTrustID Inc. (GoTrust) is the pioneer company providing a passwordless multi-factor authentication (MFA) platform for an employee’s everyday items: phone, a USB Key or their smart badge. Our mission is to make simple & secure login anywhere and anytime. With every authenticator and server certified by FIDO, GoTrust Authentication Platform makes every employee become their own ID, having effortless login to their computer, corporate systems and cloud services. GoTrustID has twenty-four international patents granted, including six US patents.
GoTrust FIDO2 Security Level 2 Idem Key is available on Amazon. https://www.amazon.com/dp/B07YTL3Q1Y?ref=myi_title_dp
About CZ.NIC
CZ.NIC, z. s. p. o., is an interest association of legal entities, founded in 1998. The association currently has 117 members. One key activity of the association is the operation of the domain name registry for the .CZ domain. The association is now intensively working on development of the mojeID service supporting new technologies and projects beneficial to the Internet infrastructure in the Czech Republic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005056/en/
Contact information
Kevin Lee
+82.10.9232.5467
kevin.lee@gotrustid.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom